Related references
Note: Only part of the references are listed.Multiple myeloma
Shaji K. Kumar et al.
NATURE REVIEWS DISEASE PRIMERS (2017)
ARNT is a potential direct HIF-1 target gene in human Hep3B hepatocellular carcinoma cells
Markus Mandl et al.
CANCER CELL INTERNATIONAL (2017)
ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple Myeloma
Matteo Marchesini et al.
CANCER CELL (2017)
Hypoxia and Inflammation in Cancer, Focus on HIF and NF-κB
Laura D'Ignazio et al.
BIOMEDICINES (2017)
Proteasome inhibitors and IMiDs can overcome some high-risk cytogenetics in multiple myeloma but not gain 1q21
Hareth Nahi et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2016)
Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management
S. Vincent Rajkumar
AMERICAN JOURNAL OF HEMATOLOGY (2016)
Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group
Pieter Sonneveld et al.
BLOOD (2016)
Gene Expression Profiles in Myeloma: Ready for the Real World?
Raphael Szalat et al.
CLINICAL CANCER RESEARCH (2016)
Progress and Paradigms in Multiple Myeloma
Kenneth C. Anderson
CLINICAL CANCER RESEARCH (2016)
Integration of Novel Agents into the Care of Patients with Multiple Myeloma
Robert Z. Orlowski et al.
CLINICAL CANCER RESEARCH (2016)
Hypoxia-inducible factors: a central link between inflammation and cancer
Daniel Triner et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
The ever-expanding role of HIF in tumour and stromal biology
Edward L. LaGory et al.
NATURE CELL BIOLOGY (2016)
Hypoxic control of metastasis
Erinn B. Rankin et al.
SCIENCE (2016)
Aryl hydrocarbon receptor nuclear translocator (ARNT) isoforms control lymphoid cancer cell proliferation through differentially regulating tumor suppressor p53 activity
Kacie A. Gardella et al.
ONCOTARGET (2016)
Hypoxia-Inducible Factors: Master Regulators of Cancer Progression
Luana Schito et al.
TRENDS IN CANCER (2016)
Treatment options for relapsed and refractory multiple myeloma
Ajay K. Nooka et al.
BLOOD (2015)
NEDD8 Inhibition Overcomes CKS1B-Induced Drug Resistance by Upregulation of p21 in Multiple Myeloma
Junwei Huang et al.
CLINICAL CANCER RESEARCH (2015)
Biomarker: Predictive or Prognostic?
Karla V. Ballman
JOURNAL OF CLINICAL ONCOLOGY (2015)
Defining and treating high-risk multiple myeloma
S. Z. Usmani et al.
LEUKEMIA (2015)
The expression level of the transcription factor Aryl hydrocarbon receptor nuclear translocator (ARNT) determines cellular survival after radiation treatment
Markus Mandl et al.
RADIATION ONCOLOGY (2015)
LDL suppresses angiogenesis through disruption of the HIF pathway via NF-κB inhibition which is reversed by the proteasome inhibitor BSc2118
Gang Yao et al.
ONCOTARGET (2015)
A Bim-targeting strategy overcomes adaptive bortezomib resistance in myeloma through a novel link between autophagy and apoptosis
Shuang Chen et al.
BLOOD (2014)
Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances angiogenesis by targeting factor-inhibiting HIF-1
Tomohiro Umezu et al.
BLOOD (2014)
HIF-1α of Bone Marrow Endothelial Cells Implies Relapse and Drug Resistance in Patients with Multiple Myeloma and May Act as a Therapeutic Target
Roberto Ria et al.
CLINICAL CANCER RESEARCH (2014)
Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with bortezomib but copy number variation and percentage of plasma cells involved have no additional prognostic value
Gang An et al.
HAEMATOLOGICA (2014)
The Role of Hypoxia and Exploitation of the Hypoxic Environment in Hematologic Malignancies
Barbara Muz et al.
MOLECULAR CANCER RESEARCH (2014)
The Aryl Hydrocarbon Receptor Nuclear Translocator (ARNT/HIF-1β) is Influenced by Hypoxia and Hypoxia-Mimetics
Matthias Wolff et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2013)
Long-Term Analysis of the IFM 99 Trials for Myeloma: Cytogenetic Abnormalities [t(4;14), del(17p), 1q gains] Play a Major Role in Defining Long-Term Survival
Herve Avet-Loiseau et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3
John D. Shaughnessy et al.
BLOOD (2011)
Disruption of IκB Kinase (IKK)-mediated RelA Serine 536 Phosphorylation Sensitizes Human Multiple Myeloma Cells to Histone Deacetylase (HDAC) Inhibitors
Yun Dai et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
The emerging role of hypoxia, HIF-1 and HIF-2 in multiple myeloma
S. K. Martin et al.
LEUKEMIA (2011)
Classical and/or alternative NF-κB pathway activation in multiple myeloma
Yulia N. Demchenko et al.
BLOOD (2010)
The NF (Nuclear factor)-κB inhibitor parthenolide interacts with histone deacetylase inhibitors to induce MKK7/JNK1-dependent apoptosis in human acute myeloid leukaemia cells
Yun Dai et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Low bone marrow oxygen tension and hypoxia-inducible factor-1α overexpression characterize patients with multiple myeloma: role on the transcriptional and proangiogenic profiles of CD138+ cells
S. Colla et al.
LEUKEMIA (2010)
The Aryl Hydrocarbon Nuclear Translocator Alters CD30-Mediated NF-κB-Dependent Transcription
Casey W. Wright et al.
SCIENCE (2009)
NF-κB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1α
Jordi Rius et al.
NATURE (2008)
A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1
John D. Shaughnessy et al.
BLOOD (2007)
CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27(Kip1)-dependent and -independent mechanisms
Fenghuang Zhan et al.
BLOOD (2007)
Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma
R. Fonseca et al.
LEUKEMIA (2006)
Multiple myeloma patients with CKS1B gene amplification have a shorter progression-free survival post-autologous stem cell transplantation
Hong Chang et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
The molecular classification of multiple myeloma
Fenghuang Zhan et al.
BLOOD (2006)
Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation
Ichiro Hanamura et al.
BLOOD (2006)
Significant increase of CKS1B amplification from monoclonal gammopathy of undetermined significance to multiple myeloma and plasma cell leukaemia as demonstrated by interphase fluorescence in situ hybridisation
Hong Chang et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
Combined treatment with the checkpoint abrogator UCN-01 and MEK1/2 inhibitors potently induces apoptosis in drug-sensitive and -resistant myeloma cells through an IL-6-independent mechanism
Y Dai et al.
BLOOD (2002)
Targeting of HIF-α to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation
P Jaakkola et al.
SCIENCE (2001)
Share Paper
